| Case n./age/sex | BCVA 1 (RE/LE) | BCVA 2 (RE/LE) | DMARDs 1 | DMARDs 2 | Infliximab therapy | Adverse effects to infliximab |
| 1/30/M | HM/1 | HM/1.3 | AZA/CSA | AZA/ADA | Suspended (loss of efficacy) | no |
| 2/39/M | 0/1 | 0/1 | CSA | CSA | Continued | no |
| 3/28/M | 1/1 | 0/0 | CSA | CSA | Continued | no |
| 4/46/F | HM/HM | 1.79/HM | CSA | - | Continued | no |
| 5/23/M | 0.15/0.69 | 0.15/0.69 | AZA | AZA | Continued | no |
| 6/30/M | 1/0 | 0.22/0 | CSA | Colch/ADA | Suspended (loss of efficacy) | no |
| 7/31/M | HM/0.3 | HM/0.045 | CSA | - | Continued | no |
| 8/28/F | 0.15 | 0.22 | AZA | AZA | Continued | no |
| 9/48/F | 0/2.09 | 0.096/2.09 | AZA/CSA | - | Continued | no |
| 10/64/F | 1.48 | HM | CSA | - | Continued | no |
| 11/49/F | 0.22/0.39 | 0.3/0.15 | CSA/Colch | AZA/Colch | Continued | no |
| 12/49/M | 0/0.045 | 0/0.045 | CSA | - | Continued | no |
| 13/43/M | 0.045/0.15 | 0.045/0.69 | AZA/CSA | AZA/ADA | Suspended (loss of efficacy) | no |
| 14/61/F | 0.22/0.69 | 0.22/0.69 | CSA | CSA | Continued | no |
| 15/42/M | 0 | 0 | AZA/CSA | CSA/ INFα | Suspended (adverse effect) | acute bronchitis |
| 16/48/F | 0.69 | 1 | CSA | CSA/ADA | Suspended (adverse effect/loss of efficacy) | acute bronchitis |
| 17/32/M | 0/0.39 | 0.22/1 | CSA | CSA/INFα | Suspended (lack of effect) | no |
| 18/71/F | 1/0.3 | 1/0.3 | CSA | MTX | Continued | no |
| 19/65/F | 0/0.3 | 0/0.096 | AZA | AZA/ | Continued | no |
| 20/20/M | 1.79/1.3 | 1/1 | AZA/CSA | AZA | Continued | no |
| 21/26/M | 0.096/0.096 | 0/0 | AZA | - | Continued | no |
| 22/47/F | HM/1 | HM/1 | AZA/CSA | AZA | Continued | no |
| 23/32/M | 0.15 | 0.15 | CSA | - | Continued | no |
| 24/28/M | 0.69 | 0.69 | AZA | AZA | Continued | no |
| 25/62/F | 1.79/1.79 | 1.48/1.79 | AZA/CSA | AZA | Continued | no |
| 26/34/M | 0.096 | 0.096 | CSA | AZA | Continued | no |
| 27/37/M | 1.79/1.79 | 1.48/1.79 | AZA | MTX | Continued | no |
| 28/56/M | 0.69/1.79 | 1.79/2.09 | CSA | - | Continued | no |
| 29/57/M | 2.09/1 | 2.09/1.79 | CSA | Colch/ADA | Suspended (loss of efficacy) | no |
| 30/32/M | 0/0.096 | -0.04/0.045 | AZA/CSA | - | Continued | no |
| 31/13/M | 0.39 | 0.39 | CSA | CSA/ADA | Suspended (loss of efficacy) | no |
| 32/34/M | 1.79/0.15 | HM/0.045 | CSA | CSA | Continued | no |